Schering-Plough (SGP) Announces Hepatitis C Data Presentations
More News related to SGP
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
- Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings
- SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
A total of 20 oral and poster presentations on clinical studies with Schering-Plough's (NYSE: SGP)hepatitis products, including PEGINTRON and REBETOL combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir, the company's investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.
Related Categories
FDAStocks Mentioned
+2.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
